SCHEMBL3397570

SCHEMBL3397570

c1ccc(-c2ccccc2-c2nnn[nH]2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DCUN1D1 Q96GG9 2/20 0.47
DCUN1D2 Q6PH85 1/20 0.47
NISCH Q9Y2I1 1/20 0.38
METAP2 P50579 1/20 0.38
AKT1 P31749 1/20 0.37
AKT2 P31751 1/20 0.37
LMNA P02545 1/20 0.37
MAP4K4 O95819 1/20 0.37
CSF1R P07333 1/20 0.37
FGFR1 P11362 1/20 0.37
PDGFRA P16234 1/20 0.37
LTK P29376 1/20 0.37
KDR P35968 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37
LIMK1 P53667 1/20 0.37
CDK5 Q00535 1/20 0.37
ACVR1 Q04771 1/20 0.37
TNK2 Q07912 1/20 0.37
AURKB Q96GD4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29499607 1.00 DCUN1D1 (0.47) DCUN1D1DCUN1D2NISCHMETAP2AKT1
SCHEMBL29034386 0.96 DCUN1D1 (0.45) DCUN1D1DCUN1D2NISCHMETAP2AKT1
SCHEMBL12615990 0.89 ALDH1A1 (0.38) DCUN1D1DCUN1D2ALDH1A1
Benzylamine SCHEMBL27675029 0.87 DPP4 (0.43) DCUN1D1DCUN1D2METAP2AKT2LMNA
Methylbiphenyl Tetrazole SCHEMBL1774035 0.85 NR1H2 (0.39) DCUN1D1DCUN1D2LMNAALDH1A1HPGD
SCHEMBL8035241 0.85 KDR (0.41) DCUN1D1DCUN1D2AKT1LMNAMAP4K4
SCHEMBL4794234 0.85 DCUN1D1 (0.36) DCUN1D1DCUN1D2
SCHEMBL9155822 0.85 ABL1 (0.47) DCUN1D1DCUN1D2HSD17B10BCL2L1NPC1
SCHEMBL4712959 0.85 DCUN1D1 (0.36) DCUN1D1DCUN1D2NISCH
Methylbiphenyl Tetrazole SCHEMBL29457258 0.85 NR1H2 (0.39) DCUN1D1DCUN1D2LMNAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US claimed
EP-2726515-B1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NAT RECH SCIENT (FR) 2015-04-01 EP claimed
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2014-07-24 US claimed
JP-2005538152-A 2005-12-15 JP claimed
EP-1537075-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2005-06-08 EP claimed
WO-2004022529-A2 DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS NEUROSEARCH A/S (DK) 2004-03-18 WO claimed
JP-3098772-B2 2000-10-16 JP claimed
EP-0527851-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-02-24 EP claimed
WO-1991017148-A1 1H-SUBSTITUTED-1,2,4-TRIAZOLE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-11-14 WO claimed
JP-5155884-A None JP disclosed
JP-5271205-A None JP disclosed
CN-117672401-A Structure-activity relation model for predicting acute oral toxicity of tetrazole compound mice and construction method 兵器工业卫生研究所 2024-03-08 CN disclosed
CN-111592500-A ARB-NEPi compound, crystal form, preparation method and application 上海博志研新药物技术有限公司 2020-08-28 CN disclosed
US-9724673-B2 Supported alkoxylated organotin reactant, preparation and use for heterogeneous-phase synthesis of tetrazoles UNIVERSITE DE NANTES (FR) 2017-08-08 US disclosed
EP-0550313-A1 2-(Tetranol-5-yl)-(1,1'-biphenyl)derivatives, their preparation and use as intermediates SYNTHELABO (FR) 1993-07-07 EP disclosed
JP-H05155884-A CONDENSED PIRAZINE DERIVATIVE KYOWA HAKKO KOGYO CO LTD 1993-06-22 JP disclosed
WO-1993008169-A1 SUBSTITUTED AMINOPYRIMIDINES AS ANGIOTENSINE II ANTAGONISTS AMERICAN HOME PRODUCTS CORPORATION (US) 1993-04-29 WO disclosed
EP-0531382-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1993-03-17 EP disclosed
WO-1991018888-A1 N-SUBSTITUTED-1,2,4-TRIAZOLONE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1991-12-12 WO disclosed
CN-1048546-A Substituted imidazo-fused 6 unit heterocycle as angiotensin II antagonism medicine MERCK & CO INC (US) 1991-01-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140206825-A1 SUPPORTED ALKOXYLATED ORGANOTIN REACTANT, PREPARATION AND USE FOR HETEROGENEOUS-PHASE SYNTHESIS OF TETRAZOLES ALK, TST, TEKT1 DCUN1D1 991/4885DCUN1D2 1099/4885NISCH 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.